SEPTInvestingStart Free

SYRE SCHEDULE 13G: SEC filing

Paradigm BioCapital entities

Filed with the SEC on · accession 0001104659-26-112828

SYRE filed a SCHEDULE 13G (schedule 13g) with the SEC on Oct 1, 2026. Paradigm BioCapital entities filed a Schedule 13G joint filing agreement regarding their beneficial ownership of Spyre Therapeutics common shares. The stock moved +1.0% by the first close after the filing.

Summary of the filing

Paradigm BioCapital entities filed a Schedule 13G joint filing agreement regarding their beneficial ownership of Spyre Therapeutics common shares. The filing is a passive investment disclosure with no stated intent to influence control.

For details, click here →

Key details

IssuerSpyre Therapeutics, Inc.
FilerParadigm BioCapital Advisors LP
FilerParadigm BioCapital Advisors GP LLC
FilerParadigm BioCapital International Fund Ltd.
Authorized signatory, paradigm biocapitalDavid K. Kim
Authorized signatorySenai Asefaw, M.D.

How SYRE stock reacted

Close before

$89.03

Sep 30, 2026

First close after

+1.01%

$89.93

5 trading days

-9.19%

$80.85

Since filing

+10.96%

$98.79

✦ Ask GOAX AI about this filing — what it means for SYRE, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for SYRE?

Click here

Frequently asked questions

What did SYRE file with the SEC on Oct 1, 2026?

SYRE filed a SCHEDULE 13G (SEC filing). Paradigm BioCapital entities filed a Schedule 13G joint filing agreement regarding their beneficial ownership of Spyre Therapeutics common shares. The filing is a passive investment disclosure with no stated intent to influence control.

How do I read a SCHEDULE 13G?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).

How did SYRE stock react to this filing?

SYRE closed at $89.03 before the filing and $89.93 on Oct 1, 2026 (+1.01%). Five trading days later: $80.85 (-9.19%).

Other SYRE SEC filings

Get alerts when SYRE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
SYRE overviewSYRE analysisSYRE newsLatest SEC filings